Sign Up Today and Learn More About Aktis Oncology Stock
Invest in or calculate the value of your shares in Aktis Oncology or other pre-IPO companies through EquityZen's platform.
Aktis Oncology Stock (AKON)
Aktis Oncology is a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals.
About Aktis Oncology Stock
Founded
2021
Headquarters
Boston, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Aktis Oncology Press Mentions
Stay in the know about the latest news on Aktis Oncology
B7h3 miniprotein conjugates
patents • Apr 02, 2025
AKTIS ONCOLOGY TO PARTICIPATE IN THE 45th ANNUAL TD COWEN HEALTH CARE CONFERENCE
prnewswire • Feb 25, 2025
AKTIS ONCOLOGY TO PARTICIPATE IN THE 45th ANNUAL TD COWEN HEALTH CARE CONFERENCE
biospace • Feb 25, 2025
Decreased retention of miniproteins in kidney
patents • Feb 07, 2025
Aktis Oncology Appoints Biotech Industry Veteran Mary Thistle to its Board of Directors
prnewswire • Feb 04, 2025
Aktis Oncology Management
Leadership team at Aktis Oncology
Co-founder and Chief Business Officer
Dr. Brian Goodman
Founder
Todd Foley
Join now and verify your accreditation status to gain access to:
- Aktis Oncology Current Valuation
- Aktis Oncology Stock Price
- Aktis Oncology Management
- Available deals in Aktis Oncology and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Aktis Oncology Cap Table and Funding History by Share Class and Liquidity Preferences
- Aktis Oncology Revenue and Financials
- Aktis Oncology Highlights
- Aktis Oncology Business Model
- Aktis Oncology Risk Factors
- Aktis Oncology Research Report from SACRA Research
Trading Aktis Oncology Stock
How to invest in Aktis Oncology stock?
Accredited investors can buy pre-IPO stock in companies like Aktis Oncology through EquityZen funds. These investments are made available by existing Aktis Oncology shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Aktis Oncology stock?
Shareholders can sell their Aktis Oncology stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
